Emerging noninvasive biochemical measures to predict cardiovascular risk

Archives of Internal Medicine

Volumn 159, Issue 3, 1999, Pages 237-245

  Pahor, Marco ^a   Elam, Marshall B ^a   Garrison, Robert J ^a   Kritchevsky, Stephen B ^a   Applegate, William B ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANTIOXIDANT; BIOCHEMICAL MARKER; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOKINE; D DIMER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; LIPID HYDROPEROXIDE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR; PROSTANOID; SELECTIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN;

ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FIBRINOLYSIS; HUMAN; INFECTION; INFLAMMATION; LIPID METABOLISM; LIPOPROTEIN METABOLISM; OXIDATIVE STRESS; PRIORITY JOURNAL; RACE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SEX; VASCULAR ENDOTHELIUM; VITAMIN METABOLISM;

BIOLOGICAL MARKERS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CONTINENTAL POPULATION GROUPS; ENDOTHELIUM, VASCULAR; HOMOCYSTEINE; HUMANS; INFLAMMATION; LIPIDS; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; RISK; RISK FACTORS; SEX FACTORS;

EID: 0033535117     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.3.237     Document Type: Review

References (144)

1. 1997 Joint National Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: 2413-2446.
2. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997; 336:1276-1282.
3. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med. 1997;157:1170-1176.
4. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996;276:544-548.
5. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation. 1994;90:1688-1695.
6. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997;96:1390-1397.
7. Brown SA, Morrisett JD, Boerwinkle E, Hutchinson R, Patsch W. The relation of lipoprotein(a) concentrations and apolipoprotein[a] phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1993; 13:1558-1566.
8. Schreiner PJ, Chambless LE, Brown SA, Watson RL, Toole J, Heiss G. Lipoprotein(a) as a correlate of stroke and transient ischemic attack prevalence in a biracial cohort: the ARIC Study -Atherosclerosis Risk in Communities. Ann Epidemiol. 1994;4:351-359.
9. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R. Race and gender differences in the association of Lp(a) with carotid artery wall thickness: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 1996;16:471-478.
10. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614.
11. Groenemeijer BE, Hallman MD, Reymer PW, et al. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients: the Ser447-stop substitution in the lipoprotein lipase gene - REGRESS Study Group. Circulation. 1997;95:2628-2635.
12. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97:2917-2923.
13. Cohen JC, Wang Z, Grundy SM, Stoesz MR, Guerra R. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest. 1994;94:2377-2384.
14. Chen L, Patsch W, Boerwinkle E. HindIII DNA polymorphism in the lipoprotein lipase gene and plasma lipid phenotypes and carotid artery atherosclerosis. Hum Genet. 1996;98:551-556.
15. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med. 1998;338:86-93.
16. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17:1053-1059.
17. Arai T, Yamashita S, Sakai N, et al. A novel non-sense mutation (G181X) in the human cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. J Lipid Res. 1996;37:2145-2154.
18. Hill SA, Nazir DJ, Jayaratne P, Bamford KS, McQueen MJ. Mutations in cholesteryl ester transfer protein and hepatic lipase in a North American population. Clin Biochem. 1997;30:413-418.
19. Bagdade JD, Kelley DE, Henry RR, Eckel RH, Ritter MC. Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipase activities in NIDDM. Diabetes. 1997;46:414-420.
20. Gudnason V, Thormar K, Humphries SE. Interaction of the cholesteryl ester transfer protein 1405V polymorphism with alcohol consumption in smoking and non-smoking healthy men, and the effect on plasma HDL cholesterol and apoAl concentration. Clin Genet. 1997;51: 15-21.
21. Ettinger WH Jr, Verdery RB, Wahl PW, Fried LP. High density lipoprotein cholesterol subtractions in older people. J Gerontol. 1994;49:M116-M122.
22. Foger B, Luef G, Ritsch A, et al. Relationship of high-density lipoprotein subtractions and cholesteryl ester transfer protein in plasma to carotid artery wall thickness. J Mol Med. 1995;73: 369-372.
23. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb. 1994;14:1767-1774.
24. Campos H, Genest JJ Jr, Blijlevens E, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12: 187-195.
25. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
26. Hodis HN, Mack WJ, Dunn M, Liu C, Selzer RH, Krauss RM. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;95:2022-2026.
27. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
28. Weintraub MS, Grosskopf I, Rassin T, et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ. 1996;312: 936-939.
29. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96:2520-2525.
30. Ma J, Folsom AR, Lewis L, Eckfeldt JH. Relation of plasma phospholipid and cholesterol ester fatty acid composition to carotid artery intima-media thickness: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr. 1997; 65:551-559.
31. Di Minno G, Grandone E, Margaglione M. Clinical relevance of polymorphic markers of arterial thrombosis. Thromb Haemost. 1997;78: 462-466.
32. Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. 1992;12:1214-1226.
33. Sechi LA, Kronenberg F, De Carli S, et al. Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension. JAMA. 1997;277:1689-1695.
34. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: The Framingham Offspring Study. JAMA. 1994;272: 1666-1671.
35. de Andrade M, Thandi I, Brown S, Gotto A Jr, Patsch W, Boerwinkle E. Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis Am J Hum Genet. 1995;56: 1379-1390.
36. Nakajima K, Saito T, Tamura A, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 1993;223:53-71.
37. Shimizu H, Mori M, Saito T. An increase of serum remnant-like particles in non-insulin-dependent diabetic patients with microalbuminuria. Clin Chim Acta. 1993;221:191-196.
38. Akkus I, Saglam NI, Caglayan O, Vural H, Kalak S, Saglam M. Investigation of erythrocyte membrane lipid peroxidation and antioxidant defense systems of patients with coronary artery disease (CAD) documented by angiography. Clin Chim Acta. 1996;244:173-180.
39. Shanmugasundaram KR, Srinivas K, Sundaram P, et al. Lipid peroxidation, antioxidant defences and red-cell membrane changes in relation to coronary risk index and symptomatic coronary heart disease. J Cardiovasc Risk. 1995;2: 551-561.
40. Romon M, Nuttens MC, Theret N, et al. Comparison between fat intake assessed by a 3-day food record and phospholipid fatty acid composition of red blood cells: results from the Monitoring of Cardiovascular Disease-Lille Study. Metabolism. 1995;44:1139-1145.
41. Chi Y, Mota de Freitas D, Sikora M, Bansal VK. Correlations of Na+-Li+ exchange activity with Na+ and Li+ binding and phospholipid composition in erythrocyte membranes of white hypertensive and normotensive individuals: a nuclear magnetic resonance investigation. Hypertension. 1996;27:456-464.
42. Laurenzi M, Cirillo M, Panarelli W, et al. Baseline sodium-lithium countertransport and 6-year incidence of hypertension: The Gubbio Population Study. Circulation. 1997;95:581-587.
43. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
44. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
45. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775-1781.
46. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methytenetetrahydrofolate reductase gene. Circulation. 1997;96: 412-417.
47. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997;95:1777-1782.
48. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
49. Morita H, Taguchi J, Kurihara H, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997;95: 2032-2036.
50. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 1994;40:873-881.
51. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
52. Huber P, Laurent M, Dalmon J. Human beta-fibrinogen gene expression: upstream sequences involved in its tissue specific expression and its dexamethasone and interleukin 6 stimulation. J Biol Chem. 1990;265:5695-5701.
53. Stein D, Heins M, Schoebel FC, et al. Activation of the fibrinolytic system in patients with coronary artery disease and hyperfibrinogenemia. Thromb Haemost. 1997;77:970-974.
54. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: the ARIC Study -Atherosclerosis Risk in Communities Study. Circulation. 1995;91:284-290.
55. Juhan Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group - European Concerted Action on Thrombosis and Disabilities. Circulation. 1996; 94:2057-2063.
56. Held C, Hjemdahl P, Rehnqvist N, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis Study in Stockholm. Circulation. 1997;95:2380-2386.
57. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
58. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
59. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96:1102-1108.
60. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the hsk of future myocardial infarction among apparently healthy men. Circulation. 1994;90:2236-2240.
61. Cushman M, Kuller LH, Lemaitre RN, Psaty BM, Sharrett AR, Tracy RP. Plasmin generation and risk of cardiovascular disease in the elderly [abstract]. Circulation. 1997;96(suppl 1):I-100.
62. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997;95:59-62.
63. van der Bom JG, de Knijff P, Haverkate F, et al. Tissue plasminogen activator and risk of myocardial infarction: The Rotterdam Study. Circulation. 1997;95:2623-2627.
64. Ridker PM, Vaughan DE, Stampfer MJ, Glynn RJ, Hennekens CH. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA. 1994;272:929-933.
65. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: HEART Study Investigators. Circulation. 1997;96:442-447.
66. Shahar E, Folsom AR, Salomaa VV, et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 1996;93:1970-1975.
67. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
68. Morishita E, Asakura H. Jokaji H, et al. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis. 1996;120:7-14.
69. Testa R, Bonfigli AR, Piantanelli L, Manfrini S, Testa I, Gregorio F. Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1996;33:111-118.
70. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95: 995-1001.
71. van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 1994;90:362-368.
72. Peiretti F, Alessi MC, Henry M, Anfosso F, Juhan-Vague I, Nalbone G. Intracellular calcium mobilization suppresses theTNF-alpha-stimulated synthesis of PAI-1 in human endothelial cells: indications that calcium acts at a translational level. Arterioscler Thromb Vasc Biol. 1997;17: 1550-1560.
73. Jansson JH, Boman K, Nilsson TK. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol. 1993;44:485-488.
74. Zehetgruber M, Beckmann R, Gabriel H, Christ G, Binder BR, Huber K. The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters. Thromb Res. 1996;83:143-152.
75. Moriyama Y, Ogawa H, Oshima S, et al. Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction. Jpn Circ J. 1997;61:308-314.
76. Tracy RP, Bovill EG, Yanez D, et al. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly: results from The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1995;15:1269-1279.
77. de Maat MP, Green F, de Knijff P, Jespersen J, Kluft C. Factor VII polymorphisms in populations with different risks of cardiovascular disease Arterioscler Thromb Vasc Biol. 1997;17: 1918-1923.
78. Iacoviello L, Di Castelnuovo A, de Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med. 1998;338:79-85.
79. Ghaddar HB, Cortes J, Salomaa V, et al. Correlation of specific platelet activation markers with carotid arterial wall thickness. Thromb Haemost. 1995;74:943-948.
80. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61-68.
81. Cushman M, Psaty BM, Macy E, et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. ArteriosclerThromb Vasc Biol. 1996;16:1163-1169.
82. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89:2817-2821.
83. Tracy RP, Psaty BM, Tang Z, et al. Coagulation factor V genetic polymorphisms associated with cardiovascular disease in the elderly [abstract]. Circulation. 1997;96(suppl 1 ):I-100-I-101.
84. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336: 973-979.
85. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995; 332:635-641.
86. Liuzzo G, Blasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
87. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
88. Fukumoto Y, Shimokawa H, Ito A, et al. Inflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth-muscle phenotypes in pigs. J Cardiovasc Pharmacol. 1997;29:222-231.
89. Torre Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
90. Wang XL, Liu SX, Wilcken DE. Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res. 1997;34: 404-410.
91. Pfeiffer A, Middelberg Bisping K, Drewes C, Schatz H. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care. 1996;19:1113-1117.
92. Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 1997;78:273-277.
93. Papadopoulos NG, Georganas K, Skoutellas V, Konstantellos E, Lyritis GP. Correlation of interleukin-6 serum levels with bone density in post-menopausal women. Clin Rheumatol. 1997;16: 162-165.
94. Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci. 1997;52: M201-208.
95. Cambien F, Ricard S, Troesch A, et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure: The Etude Cas-Tetmoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension. 1996;28:881-887.
96. Fernandez-Real JM, Gutierrez C, Ricart W, et al. The TNF-alpha gene Nco I polymorphism influences the relationsbip among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes. 1997;46:1468-1472.
97. Murray RE, McGuigan F, Grant SF, Reid DM, Ralston SH. Polymorphisms of the interteukin-6 gene are associated with bone mineral density. Bone. 1997;21:89-92.
98. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-407.
99. Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 1995; 311:711-714.
100. Sorlie PD, Adam E, Melnick SL, et al. Cytomegalovirus/herpesvirus and carotid atherosclerosis: the ARIC Study. J Med Virol. 1994;42: 33-37.
101. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-630.
102. Raza Ahmad A, Klassen GA, Murphy DA, et al. Evidence of type 2 herpes simplex infection in human coronary arteries al the time of coronary artery bypass surgery. Can J Cardiol. 1995; 11:1025-1029.
103. Ellis RW. Infection and coronary heart disease. J Med Microbiol. 1997;46:535-539.
104. Rathbone B, Martin D, Stephens J, Thompson JR, Samani NJ. Helicobacter pylori seropositivity in subjects with acute myocardial infarction. Heart. 1996;76:308-311.
105. Mendall MA, Carrington D, Strachan D, et al. Chlamydia pneumoniae. risk factors for seropositivity and association with coronary heart disease J Infect. 1995;30:121-128.
106. Belch JJ, Shaw JW, Kirk G, et al. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation. 1997;95:2027-2031.
107. Blann AD, Lip GY, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost. 1997;77:1077-1080.
108. Blann AD, Amiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol. 1997;59:115-120.
109. Morisaki N, Saito I, Tamura K, et al. New indices of ischemic heart disease and aging: studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease. Atherosclerosis. 1997;131: 43-48.
110. Hackman A, Abe Y, Insull W Jr, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996;93:1334-1338.
111. Hwang S, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96:4219-4225.
112. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
113. Wenzel K, Ernst M, Rohde K, Baumann G, Speer A. DNA polymorphisms in adhesion molecule genes: a new risk factor for early atherosclerosis. Hum Genet. 1996;97:15-20.
114. Wenzel K, Blackburn A, Ernst M, et al. Relationship of polymorphisms in the renin-angiotensin system and in E-selectin of patients with early severe coronary heart disease. J Mol Med. 1997; 75:57-61.
115. Salomone OA, Elliott PM, Calvino R, Holt D, Kaski JC. Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J Am Coll Cardiol. 1996;28:14-19.
116. Bennetl MR, Littlewood TD, Schwartz SM, Weissberg PL. Increased sensitivity of human vascular smooth muscle cells from atherosclerotic plaques to p53-mediated apoptosis. Circ Res. 1997;81:591-599.
117. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995;95:2266-2274.
118. Cai W, Devaux B, Schaper W, Schaper J. The role of Fas/APO1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis. 1997;131:177-186.
119. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 1996;94:708-712.
120. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemia heart disease. N Engl J Med. 1995;332:706-711.
121. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.
122. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996;334:1156-1162.
123. Gale CR, Martyn CN, Winter PD, Cooper C. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. BMJ. 1995;310:1563-1566.
124. Rapola JM, Virtamo J, Ripatti S, et al. Randomized trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349:1715-1720.
125. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-1456.
126. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-1449.
127. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145-1149.
128. Nyyssonen K, Parviainen MT, Salonen R, Tuomilehto J, Salonen JT. Vitamin C deficiency and risk of myocardial infarction: prospective study of men from eastern Finland. BMJ. 1997;314: 634-638.
129. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96:1755-1760.
130. Salonen JT, Nyyssonen K, Salonen R, et al. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation. 1997;95:840-845.
131. Pratico D, Iuliano L, Mauriello A, et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest. 1997;100: 2028-2034.
132. Hingorani AD, Liang CF, Fatibene J, et al. A common variant of the endothelial nitric oxide synthase gene is a risk factor for coronary atherosclerosis in the East Anglian region of the UK [abstract]. Circulation. 1997;96(suppl1):I-545.
133. Reed DM. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol. 1990;131:579-588.
134. Gillum RF. Sudden cardiac death in Hispanic Americans and African Americans. Am J Public Health. 1997;87:1461-1466.
135. Gillum RF, Mussolino ME, Madans JH. Coronary heart disease incidence and survival in African-American women and men: The NHANES I Epidemiologic Follow-up Study. Ann Intern Med. 1997;127:111-118.
136. Reeves MJ, Remington PL, Nashold R, Pete J. Chronic disease mortality among Wisconsin Native American Indians, 1984-1993. Wis Med J. 1997;96:27-32.
137. Gillum RF. Epidemiology of stroke in Hispanic Americans. Stroke. 1995;26:1707-1712.
138. Gillum RF. The epidemiology of stroke in Native Americans. Stroke. 1995;26:514-521.
139. Wild SH, Laws A, Fortmann SP, Varady AN, Byrne CD. Mortality from coronary heart disease and stroke for six ethnic groups in California, 1985 to 1990. Ann Epidemiol. 1995;5:432-439.
140. Howard G, Anderson R, Sorlie P, Andrews V, Backlund E, Burke GL. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks: the National Longitudinal Mortality Study. Stroke. 1994;25:2120-2125.
141. Gillum RF. Stroke in blacks. Stroke. 1988;19: 1-9.
142. Howard G, Manolio TA, Burke GL, Wolfson SK, O'Leary DH. Does the association of risk factors and atherosclerosis change with age? an analysis of the combined ARIC and CHS cohorts - the Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health Study (CHS) investigators. Stroke. 1997;28:1693-1701.
143. Hutchinson RG, Watson RL, Davis CE, et al. Racial differences in risk factors for atherosclerosis: the ARIC Study - Atherosclerosis Risk in Communities. Angiology. 1997;48:279-290.
144. Manolio TA, Burke GL, Psaty BM, et al. Black-white differences in subclinical cardiovascular disease among older adults: the Cardiovascular Health Study - CHS Collaborative Research Group. J Clin Epidemiol. 1995;48:1141-1152.